Appointments: Pfizer, Lilly, Theramex, Evox Therapeutics, Syros, Spruce Biosciences, Rexgenero
Executive Summary
The week's round-up includes a new CEO at Evox Therapeutics, a COO at Pfizer, new senior vice presidents at Lilly and Biohaven Pharmaceuticals, a chief business officer at Syros, a board member at Spruce Biosciences, and a new chair at Theramex; an appointment has also been made to the scientific advisory board of Rexgenero.
You may also be interested in...
Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually
Essential Health Group President Angela Hwang, Biosimilars President Richard Blackburn and US Biosimilars General Manager John Kennedy discuss the early challenges Pfizer has faced with Inflectra and optimism for the US biosimilars market over the long term.
Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually
Essential Health Group President Angela Hwang, Biosimilars President Richard Blackburn and US Biosimilars General Manager John Kennedy discuss the early challenges Pfizer has faced with Inflectra and optimism for the US biosimilars market over the long term.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.